Pulmonary Hypertension
An overview of pulmonary hypertension groups, right-heart catheterisation and specialised treatment.
Pulmonary hypertension is an elevation of pressure in the pulmonary circulation. It is not a single disease: causes include pulmonary arterial hypertension, left-heart disease, lung disease or hypoxia, chronic thromboembolic obstruction and less common mixed mechanisms.
Diagnostic Pathway
Progressive breathlessness, fatigue, chest discomfort, fainting and swelling may occur. Echocardiography estimates probability but does not by itself establish the haemodynamic diagnosis. Right-heart catheterisation is required to confirm and classify pulmonary hypertension when specialised treatment is being considered. Lung testing, imaging, blood tests and ventilation-perfusion scanning help identify the cause.
Treatment
Management is directed by the pulmonary-hypertension group. Pulmonary arterial hypertension may require combination targeted therapy and structured risk reassessment in an expert centre. Chronic thromboembolic disease requires evaluation for pulmonary endarterectomy, balloon pulmonary angioplasty or medical therapy. Drugs used for pulmonary arterial hypertension can be inappropriate in other groups.
Fainting, rapidly worsening breathlessness or signs of right-heart failure require urgent assessment.
Clinical Depth and Risk Assessment
Risk is not defined by the diagnostic label alone. Symptoms, ECG and rhythm findings, ventricular function, myocardial scar or structural change, family history, associated disease and previous events are integrated. Genetic results, when relevant, require expert interpretation; a variant of uncertain significance is not equivalent to a diagnosis.
Diagnostic Strategy and Limitations
Testing is selected to answer a specific question. ECG, ambulatory monitoring, echocardiography, cardiac MRI, CT, laboratory testing, exercise assessment or invasive evaluation have complementary roles. A normal test may not exclude an intermittent disorder, while an abnormal measurement must be checked against technical quality and clinical probability.
Treatment Decision Framework
Treatment may combine risk-factor control, condition-specific medicines, rhythm or heart-failure therapy, catheter procedures, surgery and implanted devices. These options address different mechanisms and are not automatically substitutes for one another. Expected benefit, uncertainty, procedural burden and the patient’s informed preferences should be discussed explicitly.
Long-Term Follow-up
Follow-up assesses symptoms, exercise capacity, rhythm burden, ventricular function and treatment tolerance over time. Family screening may be appropriate in inherited or suspected inherited disease. New fainting, sustained rapid rhythm, chest pain, neurological symptoms or rapidly worsening breathlessness requires urgent assessment.
Questions to Discuss With the Cardiology Team
- Which finding has the greatest influence on my present risk?
- Which test or treatment would genuinely change management?
- What symptoms should lead to an earlier appointment or emergency care?
- Do relatives need clinical or genetic assessment?
Medical Information Note
This page supports an informed discussion with the clinical team. It does not provide a personal diagnosis, medicine dose or sports-clearance decision.